Sanctuary Advisors LLC Makes New $945,000 Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Sanctuary Advisors LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 3,139 shares of the biopharmaceutical company’s stock, valued at approximately $945,000.

Several other hedge funds have also recently modified their holdings of the business. Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $243,000. Geneos Wealth Management Inc. boosted its position in Alnylam Pharmaceuticals by 372.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 175 shares in the last quarter. Flow Traders U.S. LLC bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $241,000. Daiwa Securities Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares during the period. Finally, NewEdge Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 70,300.0% in the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 703 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ALNY shares. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 31st. BMO Capital Markets initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, August 19th. They set an “outperform” rating and a $318.00 price objective on the stock. Sanford C. Bernstein reiterated an “outperform” rating and issued a $376.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday. Chardan Capital reiterated a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Finally, Truist Financial decreased their price target on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $386.14.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $236.56 on Friday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The firm has a market cap of $31.65 billion, a PE ratio of 43.97 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $495.55. The stock has a fifty day moving average price of $263.44 and a 200-day moving average price of $294.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the previous year, the business earned ($0.51) EPS. The firm’s revenue for the quarter was up 66.9% on a year-over-year basis. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.